The vaccine was approved. But the scrutiny had only just begun.
Em meio à corrida global por vacinas, Minas Gerais obteve, em 2 de julho de 2021, a autorização da Anvisa para importar 428 mil doses da Sputnik V russa — suficientes para imunizar 214 mil pessoas. A aprovação, cercada de 22 condições rigorosas, reflete a tensão entre a urgência de ampliar a vacinação e a cautela regulatória diante de um imunizante ainda sem registro formal no Brasil. O estado avança, mas carrega sobre si o peso da responsabilidade legal e da vigilância contínua.
- Minas Gerais aguardava há meses uma resposta da Anvisa, e a aprovação chegou com força — mas também com 22 condições que transformam cada etapa da vacinação em um ato de prestação de contas.
- A restrição a apenas 1% da população estadual e a exclusão de gestantes, lactantes e pessoas com comorbidades graves revelam o quanto a agência ainda desconfia dos padrões de fabricação russos.
- Antes de qualquer dose ser aplicada, a Fiocruz precisará analisar e liberar cada lote, criando um gargalo técnico que pode atrasar a chegada efetiva das vacinas aos braços mineiros.
- O estado assume integralmente a responsabilidade jurídica pela qualidade, segurança e eficácia do imunizante — uma carga incomum que transforma o governo estadual em fiador de um produto estrangeiro.
- Com mais de 13,4 milhões de doses já recebidas do governo federal, Minas vacina em ritmo constante, mas a busca por suprimento adicional deixa clara a distância entre o que chegou e o que ainda é necessário.
Na tarde de 2 de julho, a Anvisa deu sinal verde para que Minas Gerais importasse 428 mil doses da Sputnik V, o imunizante desenvolvido pela Rússia. A decisão coroou semanas de negociações entre o governador Romeu Zema, representantes do fundo soberano russo e a agência reguladora brasileira. As doses seriam suficientes para vacinar completamente 214 mil pessoas — cerca de 1% da população do estado, exatamente o limite permitido para importações emergenciais.
Zema comemorou a aprovação e anunciou que o fundo russo trabalharia com o estado para definir uma data de entrega. O contexto era de vacinação em andamento: Minas já havia recebido mais de 13,4 milhões de doses federais entre Coronavac, AstraZeneca, Pfizer e Janssen, com 7,2 milhões de moradores com ao menos uma dose aplicada. Ainda assim, a demanda por mais insumos era evidente.
A autorização, porém, veio acompanhada de 22 condições detalhadas. As vacinas deveriam partir de duas fábricas russas específicas, inspecionadas pela Anvisa, e cada lote precisaria comprovar ausência de adenovírus replicante e passar por testes de esterilidade. Antes da distribuição, o Instituto Nacional de Controle de Qualidade em Saúde, da Fiocruz, teria de analisar e liberar cada remessa.
As restrições de uso eram igualmente severas: apenas adultos entre 18 e 60 anos poderiam receber o imunizante, excluindo gestantes, lactantes e pessoas com condições graves de saúde. A aplicação ficaria restrita a centros de referência em imunização, e os pacientes deveriam ser informados de que a Sputnik V não possuía registro nem autorização de uso emergencial pela Anvisa — apenas aprovação de reguladores estrangeiros.
A vigilância seria contínua e exigente. Eventos adversos graves teriam de ser notificados em 24 horas; outros efeitos colaterais, em cinco dias. O estado deveria enviar avaliações mensais de risco e benefício, monitorar alertas internacionais sobre a vacina e manter mapas detalhados de distribuição por lote. O governo mineiro, na condição de importador, assumia também a obrigação de garantir a cadeia de frio desde a saída da Rússia até o armazenamento local.
Com a aprovação conquistada, Minas Gerais enfrentava agora a tarefa concreta de transformar permissão regulatória em vacinação real — finalizando contratos, liberando lotes na Fiocruz e preparando os pontos de aplicação. A vacina estava autorizada. A fiscalização, porém, havia apenas começado.
On Friday, July 2nd, Minas Gerais cleared a regulatory hurdle that had been months in the making: Brazil's health surveillance agency, Anvisa, approved the state's request to import 428,000 doses of Russia's Sputnik V vaccine. The decision came after the state's leadership, including Governor Romeu Zema, had met with Russian embassy officials weeks earlier to explore the possibility. Now, with Anvisa's sign-off in hand, the state could move forward—though not without strings attached.
The 428,000 doses represented what officials called an initial purchase, enough to fully vaccinate roughly 214,000 people with the two-shot regimen. It amounted to about one percent of Minas Gerais's population, which was precisely the ceiling Anvisa had set for emergency imports. Zema welcomed the approval in a statement, noting that the Russian sovereign wealth fund would now work with state officials to set a delivery date. The governor expressed hope the doses would arrive as soon as possible.
By early July, Minas had already received more than 13.4 million vaccine doses from the federal government—a mix of Coronavac, AstraZeneca, Pfizer, and Janssen shots. Health officials reported that over 7.2 million residents had received at least one dose, while 2.7 million had completed their two-dose series. The state was vaccinating steadily, but demand for more supply was clear.
Yet Anvisa's approval came wrapped in an elaborate set of conditions, twenty-two in total, each designed to manage what the agency saw as significant safety and quality risks. The vaccines had to come from two specific Russian manufacturing plants—Generium and Pharmstandard UfaVita—that Anvisa had inspected. Every batch destined for Brazil required certificates proving the absence of replicating adenovirus, along with sterility testing. Before a single dose could be administered, Brazil's national quality control institute, part of Fiocruz, would have to analyze and release each shipment.
The restrictions on who could receive the vaccine were strict. Sputnik V could only be given to adults between 18 and 60 years old. Pregnant women, nursing mothers, people with serious underlying conditions, and anyone with a history of severe allergic reactions were excluded. The state would have to distribute doses only through specialized immunization reference centers, not through ordinary vaccination sites. And crucially, the importer—in this case, the state government—bore full legal responsibility for the vaccine's quality, safety, and efficacy.
Anvisa also demanded continuous surveillance. Serious adverse events had to be reported within twenty-four hours. All other side effects and technical complaints within five days. The state would submit monthly benefit-risk assessments to Anvisa, tracking safety and effectiveness data for each imported batch. It would monitor international safety alerts issued by other countries using Sputnik V and immediately notify Anvisa of any warnings from foreign health authorities. The state would maintain detailed maps of where each batch was distributed and share quality control results with Anvisa's post-market surveillance team.
The conditions reflected deep skepticism about the Russian vaccine's manufacturing standards. Anvisa required the Russian producers to evaluate their sterilization filtration process and propose additional risk mitigation measures. The state would need to submit validation reports for the manufacturing process itself, or obtain a declaration from Russian authorities confirming they had reviewed and approved such documentation. For one of the plants, Anvisa demanded training records for operators and videos demonstrating that critical procedures in clean rooms had been corrected and posed no contamination risk.
The state government, as the importer, also inherited a long list of obligations. It had to ensure the cold chain remained unbroken from the moment the vaccine left Russia until it arrived in storage. It had to monitor temperature continuously and immediately notify Anvisa if the vaccine experienced any temperature excursion that might compromise quality. It had to inform patients that Sputnik V had no formal registration or emergency use authorization from Anvisa—only approval from a foreign regulator. And it had to establish systems to track complaints and adverse events, funneling that information back to Anvisa through official channels.
With approval in hand but conditions in place, Minas Gerais now faced the work of turning regulatory permission into actual vaccination. The Russian sovereign fund and state officials would need to finalize contract terms. Doses would need to clear quality testing at Fiocruz. Distribution sites would need to be prepared. And throughout it all, the state would be watched—by Anvisa, by international health authorities, by the public. The vaccine was approved. But the scrutiny had only just begun.
Citas Notables
The Russian sovereign wealth fund will work with state officials to set a delivery date, which the governor hopes will be as soon as possible.— Governor Romeu Zema
La Conversación del Hearth Otra perspectiva de la historia
Why did Anvisa attach so many conditions to this approval? It seems almost punitive.
It wasn't punishment—it was precaution. Sputnik V had been approved in other countries, but Anvisa had concerns about the manufacturing process itself, particularly around sterilization. They wanted guarantees before Brazilian citizens received it.
But the state had already been vaccinating millions of people with other vaccines. Why the extra caution here?
Because this was an emergency import from a foreign manufacturer Anvisa hadn't fully vetted. The other vaccines had gone through longer approval processes. With Sputnik V, they were compressing the timeline, so they built in more oversight on the back end—continuous monitoring, batch testing, adverse event reporting.
The age restriction—18 to 60—that's quite narrow. Why exclude older people?
The source material doesn't explain the reasoning, but it likely reflected limited safety data in older populations at that moment. Anvisa was being conservative, restricting use to the group where they felt most confident.
And the state is legally responsible if something goes wrong?
Yes. That's standard for importers, but it's a significant liability. The state had to guarantee the quality of a product made in another country, under another regulatory system. They were essentially putting their reputation on the line.
Did the state seem hesitant about taking on that responsibility?
The source doesn't show hesitation. Governor Zema was celebrating the approval. But you can see the weight of it in all those conditions—the monthly reports, the 24-hour adverse event reporting, the temperature monitoring. It wasn't a simple transaction. It was a commitment to constant vigilance.